Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (OBLN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
obln · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Obalon Therapeutics, Inc.You OBLN | $5M | N/A | — | — |
 Fresh Tracks Therapeutics, Inc. FRTX | $6M | N/A | — | -$0.96 |
 Greenbrook TMS Inc. GBNH | $6M | N/A | — | -$3.74 |
 LumiraDx Limited LMDX | $5M | N/A | — | -$1.59 |
 Xylo Technologies Ltd. MDGS | $179M | N/A | — | -$380.16 |
 Holdco Nuvo Group D.G Ltd. Ordinary Shares NUVO | $6M | N/A | — | -$1.64 |
 Invitae Corporation NVTA | $5M | N/A | — | -$13.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Obalon Therapeutics, Inc. (OBLN) measures how much investors pay for each dollar of the company's trailing earnings. OBLN's current PE ratio of N/A is calculated by dividing its stock price of $3.05 by its TTM earnings per share of —.
Frequently asked questions
OBLN pe ratio · 6 questionsOBLN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.05 and TTM EPS of —. Data sourced from Financial Modeling Prep via OBLN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Obalon Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09